Clinical Trial Update: Nivolumab in AML in Remission at High Risk for Relapse [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab for acute myeloid leukemia in remission at high risk for relapse has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia Arising From Myelodysplastic Syndrome
• Acute Myeloid Leukemia in Remission
• Therapy-related Myeloid Neoplasm

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Status: COMPLETED | Results posted: 2024-10-24